US Patent

US11564912 — Methods for treating irritable bowel syndrome (IBS)

Method of Use · Assigned to Salix Pharmaceuticals Inc · Expires 2029-02-26 · 3y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new methods and kits for treating irritable bowel syndrome (IBS) in specific populations, including females, older subjects, and non-white subjects.

USPTO Abstract

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.

Drugs covered by this patent

Xifaxan (rifaximin) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3511`	—	Xifaxan

Patent Metadata

Patent number: US11564912
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-26
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.